抗人CD117 CAR T细胞可有效清除表达CD117的健康和恶性造血细胞
该研究针对急性髓系白血病(AML)与造血干/祖细胞(HSPC)表面抗原高度相似的问题,提出以CD117为靶点,用CAR T细胞同时靶向健康和恶性HSPC,随后通过移植健康HSPC挽救造血。研究从健康供者和AML患者成功制备抗CD117 CAR T细胞,在体外和小鼠异种移植模型中有效清除CD117阳性细胞,并在原发CD117阳性AML小鼠中根除疾病;ATG联合利妥昔单抗可清除CAR T细胞。
要点
- 抗CD117 CAR T细胞可从健康供者和AML患者成功制备。
- 体外和小鼠体内均能清除CD117阳性健康及白血病细胞。
- 在原发CD117阳性AML小鼠治疗场景中根除疾病。
核心结论
- 研究首次提供针对表达CD117的人造血细胞生成CAR T细胞的概念验证及临床前有效性证据。
研究设计与样本
- 临床前研究:从健康供者和AML患者制备抗CD117 CAR T细胞,进行体外功能检测及小鼠异种移植模型(健康人造血、原发CD117阳性AML)评估。
主要发现
- 抗CD117 CAR T细胞在体外有效靶向健康和白血病CD117阳性细胞。
- 在移植健康人造血的小鼠中,抗CD117 CAR T细胞清除CD117阳性而非CD117阴性的人细胞。
- 在移植原发人CD117阳性AML的小鼠中,抗CD117 CAR T细胞在治疗场景下根除疾病。
- ATG联合利妥昔单抗(结合共表达的CAR T转导/选择标记RQR8)导致CAR T细胞清除。
临床怎么用
- 作者提出靶向健康和恶性HSPC的策略,该策略应可保留大多数成熟造血细胞,但需要终止CAR T并随后移植健康HSPC以挽救造血。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) initiating and sustaining cells maintain high cell-surface similarity with their cells-of-origin, i.e., hematopoietic stem and progenitor cells (HSPCs), and identification of truly distinguishing leukemia-private antigens has remained elusive to date. To nonetheless utilize surface antigen-directed immunotherapy in AML, we here propose targeting both, healthy and malignant human HSPC, by chimeric antigen receptor (CAR) T-cells with specificity against CD117, the cognate receptor for stem cell factor. This approach should spare most mature hematopoietic cells and would require CAR T termination followed by subsequent transplantation of healthy HSPCs to rescue hematopoiesis. We successfully generated anti-CD117 CAR T-cells from healthy donors and AML patients. Anti-CD117 CAR T-cells efficiently targeted healthy and leukemic CD117-positive cells in vitro. In mice xenografted with healthy human hematopoiesis, they eliminated CD117-expressing, but not CD117-negative human cells. Importantly, in mice xenografted with primary human CD117-positive AML, they eradicated disease in a therapeutic setting. Administration of ATG in combination with rituximab, which binds to the co-expressed CAR T-cell transduction/selection marker RQR8, led to CAR T-cell depletion. Thus, we here provide the first proof of concept for the generation and preclinical efficacy of CAR T-cells directed against CD117-expressing human hematopoietic cells.
引用
- Myburgh R, Kiefer JD, Russkamp NF, et al. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia. 2020. PMID: 32358567. doi:10.1038/s41375-020-0818-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。